News & Events


Tuesday March 12, 2019

Neurocrine Biosciences Reports Positive Interim Results from Phase II Study of NBI-74788 in Adults with Classic Congenital Adrenal Hyperplasia

- NBI-74788 Achieved Study Goals and Demonstrated Reductions in Key Disease Biomarkers Exceeding Predetermined Threshold for Proof-of-Concept - Based on Interim Results, Company Plans to Meet with FDA to Discuss the Registration Program in Adult and Pediatric Patients with Congenital Adrenal Hyperplasia SAN DIEGO, March 12, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced positive interim results from a Phase II proof-of-concept study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of NBI-74788, a proprietary corticotropin-releasing factor type 1 (CRF1) receptor antagonist, in adult patients with classic congenital adrenal hyper...

Tuesday March 05, 2019

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

SAN DIEGO, March 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the following investor conferences: Cowen 39th Annual Health Care Conference at 10:00 a.m. ET on Tuesday, March 12, 2019, in Boston. Barclays Global Healthcare Conference at 11:15 a.m. ET on Wednesday, March 13, 2019, in Miami. The live presentations will be webcast and may be accessed on the Company's website under Investors at A replay of the presentations will be available on the website app...

Tuesday February 05, 2019

Neurocrine Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results

INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $130.3 Million with Approximately 22,900 TRx INGREZZA® (valbenazine) Full-Year 2018 Net Product Sales of $409.6 Million with Approximately 71,500 TRx Congenital Adrenal Hyperplasia Phase II Study Initial Results Expected in Q1 2019 Neurocrine Biosciences and Voyager Therapeutics Form Strategic Gene Therapy Collaboration for Key Neuroscience Programs SAN DIEGO, Feb. 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended December 31, 2018 and provided an update on the launch of INGREZZA® (valbenazine) and its clinical development programs. ...

Tuesday January 29, 2019

Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia

Collaboration leverages strengths and efforts of both companies towards developing and commercializing life-changing treatments for severe neurological diseasesNeurocrine Biosciences gains development and commercialization rights to gene therapy programs VY-AADC for Parkinson’s disease, VY-FXN01 for Friedreich’s ataxia and two additional programs to be determinedVoyager receives $165 million upfront, along with funding for ongoing development of each program, and up to $1.7 billion in potential development, regulatory and commercial milestone paymentsSAN DIEGO and CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (N...

Wednesday January 16, 2019

New INGREZZA® (valbenazine) Analysis Published in the Journal of Affective Disorders Demonstrates Sustained Improvement in Tardive Dyskinesia Symptoms in Patients with Primary Mood Disorders

INGREZZA Significantly Reduced the Symptoms of Involuntary Movements in Patients with Bipolar or Major Depressive Disorder in Post-Hoc Analysis Patients Treated with INGREZZA Able to Remain on Existing Psychiatric Medications SAN DIEGO, Jan. 16, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that a new analysis of INGREZZA® (valbenazine) capsules, published in the Journal of Affective Disorders1, demonstrated sustained improvement in tardive dyskinesia (TD) symptoms in patients with primary mood disorders. In the post-hoc analysis, INGREZZA significantly reduced involuntary movements associated with TD in patients with a primary mood disorder, such as b...